Pharma News

Fresenius Kabi acquire mAbxience and Ivenix

Home/Pharma News | Posted 15/04/2022

Fresenius Kabi is acquiring a majority stake in biosimilars company mAbxience, and is acquiring infusion pump maker, Ivenix outright. The deals are set to be completed by mid-2022.

Cipla–mAbxience partnership in South Africa

Home/Pharma News | Posted 08/04/2022

Cipla Medpro announced a partnership agreement with the global biotechnology company mAbxience in March 2022. This aims to provide essential oncology and respiratory-related biosimilars in South Africa.

Biocon to acquire biosimilars business from Viatris

Home/Pharma News | Posted 01/04/2022

India-based biologicals specialist Biocon Biologics (Biocon) announced on 28 February 2022 that it has entered into a definitive agreement with its partner Viatris (formerly Mylan) to acquire the latter’s biosimilar business.

Private equity firms poised to bid for Sandoz takeover

Home/Pharma News | Posted 25/03/2022

Following the late 2021 reports that Novartis is considering a possible sale or spinoff of its generics (and biosimilars) unit, Sandoz [1, 2], two private equity firms are now reportedly discussing a joint bid for the unit.

AbbVie and Alvotech settle Humira (adalimumab) disputes

Home/Pharma News | Posted 18/03/2022

US firm AbbVie and Iceland-based Alvotech have announced a resolution to the patent and trade secret disputes regarding Humira (adalimumab), for which Alvotech is developing a biosimilar.

Biogen and Xbrane form agreement for arthritis biosimilar

Home/Pharma News | Posted 04/03/2022

Biogen and Xbrane Biopharma (Xbrane) have announced a commercialization and licensing agreement for a biosimilar of certolizumab pegol (Cimzia), which can be used to treat rheumatoid arthritis and other inflammatory conditions.

Axantia to market Lupin’s pegfilgrastim in the Middle East and North Africa

Home/Pharma News | Posted 25/02/2022

On 1 February 2022, Indian multinational pharmaceutical company Lupin Ltd announced that it was entering into a License, Supply and Technology Sharing agreement with Axantia, to market Lupin’s pegfilgrastim biosimilar in certain territories in the Middle East and North Africa.

Orion-CuraTeQ and Theramax-Enzene Biosciences partnerships

Home/Pharma News | Posted 18/02/2022

In January 2022, Finnish company Orion Corporation and CuraTeQ Biologics, subsidiary of India’s Aurobindo Pharma, announced their European expansion to the Baltic countries. This follows the December 2021 announcement that the UK’s Theramex entered into an agreement with India’s Enzene Biosciences to develop, register and commercialize a biosimilar of Roche’s RoActemra® (tocilizumab).

Biocon–Viatris merger expected

Home/Pharma News | Posted 11/02/2022

The merger of India’s Biocon Biologics and Viatris’ biosimilar business are reported to be in advanced stages.  

Samsung to take full control of Samsung Bioepis

Home/Pharma News | Posted 04/02/2022

Korean electronics giant Samsung has made a deal with US biotechnology company Biogen Idec (Biogen) to take full ownership of their joint biosimilars venture, Korea-based Samsung Bioepis.